SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE

V2-40U32-U3-F I 10//23.004	02-40052-US-P	10/725,064
----------------------------	---------------	------------

APPLICANT:
Summar

FILING DATE GROUP
December 1, 2003 TBD

U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE **EXAMINER** NAME CLASS SUBCLASS FILING DATE (IF APPROPRIATE) 4,284,647 AA 08/18/1981 Brusilow et al. 4,457,942 AB 07/03/1984 Brusilow AC 5,605,930 02/25/1997 Samid AD 5,635,532 06/03/1997 Samid AE 5,635,533 06/03/1997 Samid AF 5,654,333 08/05/1997 Samid AG 5,661,179 08/26/1997 Samid AΗ 5,708,025 01/13/1998 Samid ΑĪ 5,710,178 01/20/1998 Samid ΑJ 5,712,307 01/27/1998 Samid 5,843,994 AK 12/01/1998 Samid AL 5,852,056 12/22/1998 Samid 5,877,213 03/02/1999 AM Samid 03/16/1999 AN 5,883,124 Samid 5,968,979 10/19/1999 AO Brusilow AP 6,037,376 03/14/2000 Samid AQ 6,060,510 05/09/2000 Brusilow AR 6,083,984 07/04/2000 Brusilow

BA OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BA Albrecht et al., "Hepatic Encephalopathy: Molecular Mechanisms Underlying the Clinical Syndrome," J. Neurol. Sci. 1999
Nov. 30; 170(2): 138-46.

EXAMINER

Dry Los

DATE CONSIDERED

8/1/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TBD

	FEB 2 5 2004 20			SHEET 2 OF
SUBSTITUTE FORM PTO-1449	FIRM'S TRADESIBLE	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO. 02-40052-US-P	SERIAL NO. 10/725,064
INFORMA	TION DISCLOSUF	RE CITATION	APPLICANT:	
			Summar SULING DATE	CROUP
			FILING DATE	GROUP

U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE NAME CLASS **SUBCLASS EXAMINER** FILING DATE (IF APPROPRIATE) INITIAL

December 1, 2003

FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE CLASS **SUBCLASS** COUNTRY TRANSLATION TRANSLATION

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) BB Albrecht, "Roles of Neuroactive Amino Acids in Ammonia Neurotoxicity," J. Neurosci. Res. 1998 Jan. 15; 51(2): 133-8. Applegarth et al., "Incidence of Inborn Errors of Metabolism in British Columbia," 1969-1996, Pediatrics 2000 Jan.; 105(1): BC e10. BD Batshaw, "Inborn Errors of Urea Synthesis," Ann. Neurol. 1994 Feb.; 35(2): 133-41. BE Batshaw, "Hyperammonemia," Curr. Probl. Pediatr., 1984 Nov.; 14(11): 1-69. BF Becker et al., "Metabolic Disease," Textbook of Neuropathology, Baltimore: Williams & Wilkins, 1997; 487. BG Breningstall, "Neurologic Syndromes in Hyperammonemic Disorders," Pediatr. Neurol. 1986 Sept.-Oct.; 2(5): 253-62. Brusilow et al., "Urea Cycle Disorders," The Metabolic and Molecular Bases of Inherited Disease, New York: McGraw-Hill, BH 1995; 1: 1187-1232. Collins et al., "Neonatal Argininosuccinic Aciduira-Survival After Early Diagnosis and Dietary Management," J. Pediatr. BI 1980 Mar.; 96 (3 Pt. 1): 429-31. Del Rosario et al., "Hyperammonemic Encephalopathy After Chemotherapy. Survival After Treatment with Sodium Benzoate BJ and Sodium Phenylacetate," J. Clin. Gastroenterol. 1997 Dec.; 25(4): 682-4. BK Feillet et al., "Alternative Pathway Therapy for Urea Cycle Disorders," J. Inherit. Metab. Dis. 1998; 21 Suppl 1: 101-111. Felipo et al., "Molecular Mechanism of Acute Ammonia Toxicity and of its Prevention by L-Carnitine," Adv. Exp. Med. BL Biol. 1994; 368: 65-77. Hauser et al., "Allopurinol-Induced Orotidinuria. A Test for Mutations at the Ornithine Carbamoyltransferase Locus in **BM** Women," N. Engl. J. Med., 1990 Jun. 7; 322(23); 1641-5. Kuntze et al., "Hyperammonemic Coma Due to Proteus Infection," J. Urol. 1985 Nov.; 134(5): 972-3. BN Logan, "Neonatal Hyperammonemic Encephalopathy. Topics in Neonatal Neurology," Orlando: Grune & Stratton 1984; 137-BO Maestri et al., "Plasma Glutamine Concentration: A Guide in the Management of Urea Cycle Disorders," J. Pediatr. 1992 BP Aug.; 121(2): 259-61.

EXAMINER DATE CON	ONSIDERED $8/5/05$
-------------------	--------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TBD

E 2	5 2004 PS		SHEET 3 OF
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO. 02-40052-US-P	SERIAL NO. 10/725,064
INFORMATION DISC	CLOSURE CITATION		
		APPLICANT: Summar	
		FILING DATE	GROUP

U.S. PATENT DOCUMENTS

December 1, 2003

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

·	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Msall et al., "Neurologic Outcome in Children with Inborn Errors of Urea Synthesis. Outcome of Urea-Cycle
(IL)	BQ	Enzymopathies," N. Engl. J. Med., 1984 Jun. 7; 310(23): 1500-5.
	BR	Prasad et al., "Argininemia: A Treatable Genetic Cause of Progressive Spastic Diplegia Simulating Cerebral Palsy: Case Reports and Literature Review," J. Child. Neurol. 1997 Aug.; 12(5): 301-9.
	BS	Ratnaike et al., Hyperammonaemia and Hepatoxicity During Chronic Valproate Therapy: Enhancement by Combination with Other Anticpileptic Drugs," Br. J. Clin. Parmacol. 1986 Jul.; 22(1): 100-3.
	BT	Schaefer et al., "Dialysis in Neonates with Inborn Errors of Metabolism," Nephrol. Dial. Transplant, 1999 Apr.; 14(4): 910-8.
	BU	Schutze et al., "Hyperammonemia and Neonatal Herpes Simplex Pneumonitis," Pediatr. Infect. Dis. J., 1990 Oct.; 9(10): 749-50.
	BV	Uchino et al., "Neurodevelopmental Outcome of Long-term Therapy of Urea Cycle Disorders in Japan," J. Inherit. Metab. Dis. 21 1998; 21 Suppl 1: 151-9.
	BW	Whitington et al., "Liver Transplantation for the Treatment of Urea Cycle Disorders," J. Inherit Metab. Dis., 1998; 21 Suppl 1: 112-8.
	BX	Williams et al., "Valproic Acid-Induced Hyperammonemia in Mentally Retarded Adults," Neurology 1984 Apr.; 34(4): 550-3.
	BY	Petersdorf, et al., Harrison's Principles of Internal Medicine, 10th Edition, McGraw-Hill 1983; 125, 1775, 1781, 1814-16, 2108-09.
	BZ	Beers et al., The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, Merck Research Laboratories, 1999, 362-5, 372-6.
	CA	The Merck Manual, Sec. 4, Ch. 38, Clinical Features of Liver Disease, Portal-Systemic Encephalopathy, available at http://www.merck.com/pubs/mmanual/section4/chapter38/38f.htm, 6/23/2003.
	СВ	What is a Urea Cycle Disorder?, available at http://www.nucdf.org/whatis.htm, 9/25/2003.
	CC	Hepatic Encephalopathy, available at http://members.tripod.com/enotes/hepatic-encephalopathy.htm, 6/24/2003.
	CD	Excerpt from Portal-Systemic Encephalopathy, available at http://www.emedicine.com/med/byname/portal-system-encephalopathy. htm, 6/24/2003.
	CE	Watanabe, Portal-Systemic Encephalopathy in Non-Cirrhotic Patients: Classification of Clinical Types, Diagnosis and Treatment Journal of Gastroenterology and Hepatology 15(9): 969-79, available at http://archive.mail-list.com/hbv_research/msg01824.html, 6/24/2003.

EXAMINER Dy LO	DATE CONSIDERED 8/5/2005
0	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		FEB	. E		_					SH	EET 4 OF 4
SUBSTITUTE	FORM PTO	1449	RADENDE	MENT OF COMMERC		Y. DOCK 0052-US-				RIAL NO /725,064	
	INFOR	MATION DISCLO	- SURE CITAT	TION	·						
		,			APP Sum	LICANT: mar		-	_		
						NG DAT	_		GR TB	ROUP D	
			U.S	. PATENT DOC	CUMENT	rs		,			
EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATA APPROPRIA											
			FORE	IGN PATENT D	осимі	ENTS					
		DOCUMENT NO.	DATE	COUNTRY	,	CLASS SUBCLASS <u>T</u>			TRANSI YES	LATION	TRANSLATION NO
A		OTHER DO	CUMENTS (Inc	luding Author.	Title. Dat	e. Pertine	ent Pages.	Etc.)			
al	CG		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Butterworth, "Effects of Hyperammonaemia on Brain Function," J. Inher. Metab. Dis. 21 (Suppl 1) 1998; 6-20.								0.
	СН		Lee et al., "In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle," PNAS 2000 July 5, 97(14): 8021-8026.								
	CI		Way, "Portal Hypertension," Current Surgical Diagnosis & Treatment, 10th edition, Appleton & Lange; 1994: 520-536.								
	CJ	Working Party at the	Ferenci et al., "Hepatic Encephalopathy-Definition, Nomeclature, Diagnosis, and Quantification: Final Report of the Working Party at the 11 th World Congresses of Gastroenterology, Vienna, 1998", Hepatology 2002; 35(3): 716-721.								
	CK	Controlled Study," H	Sanyal et al., "Portosystemic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Results of a Prospective Controlled Study," Hepatology 1994; 20(1 Pt. 1): 46-45.								
	CL	Riggio et al., "Hepati Digestive Diseases ar	nd Sciences, 1996	March; 41(3): 5	78-584.	Ţ	•				,
	СМ	Thuluvath et al., "TIF Diseases and Science			Ascites. R	lesponse a	and Surviv	al Are B	oth Un	predictabl	le," Digestive
	CN	Groeneweg et al., "St	ıbclinical Hepatic	Encephalopathy	Impairs	Daily Fur	ctioning,"	Hepatol	ogy 19	98 July; 2	8(1): 45-49.
EXAMINER		ly Li			DATE CONS	IDERED	8/5	1200	5		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.